Treatment Information

Cancer Monthly > Treatment Information
Back

Melanoma treatment details. Chemotherapy, Biologic therapy.

The Angeles Clinic and Research Institute, Santa Monica, CA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Santa Monica, CA
Treatments:Chemotherapy, Biologic therapyHospital:The Angeles Clinic and Research Institute
Drugs:Journal:Link
Date:Jul 2011

Description:

Patients:
This phase II study involved stage IV melanoma patients who were divided into three separate treatment groups. Group A consisted of 32 patients with a median age of 64 years; 56% were male. Group B consisted of 32 patients with a median age of 60 years; 56% were male. Group C consisted of 33 patients with a median age of 61 years; 79% were male.

Treatment:
Patients in group A were treated with the chemotherapy agent dacarbazine.

Patients in group B were treated with dacarbazine and the biologic therapy agent intetumumab, which is an anti-integrin monoclonal antibody that interferes with getting blood to the tumor.

Patients in group C were treated with the biologic therapy agent intetumumab alone.

Toxicities:
The most severe adverse reactions in group A were grade 4 neutropenia, thrombocytopenia, and shortness of breath.

The most severe adverse reactions in group B were grade 4 anemia, leukopenia, and neutropenia. Grade 3 headache was also reported.

The most severe adverse reactions in group C were grade 3 fatigue, headache, and abdominal pain

Results:
The median overall survival rates for groups A, B, and C were 8, 11, and 15 months, respectively.

Support:
This study was supported by Centocor Ortho Biotech, makers of intetumumab.

Correspondence: Dr. S. O’Day ; email: [email protected]

Email Physician More Information


Back